Jonathan Wolleben
Stock Analyst at Citizens
(4.54)
# 242
Out of 5,162 analysts
241
Total ratings
51.26%
Success rate
26.78%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRB Spruce Biosciences | Maintains: Market Outperform | $180 → $170 | $60.06 | +183.05% | 10 | Mar 10, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Market Outperform | $105 → $96 | $37.49 | +156.07% | 19 | Mar 2, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Market Outperform | $167 → $176 | $87.38 | +101.42% | 7 | Feb 27, 2026 | |
| GPCR Structure Therapeutics | Maintains: Market Outperform | $120 → $113 | $53.75 | +110.23% | 12 | Feb 27, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Market Outperform | $102 → $112 | $92.36 | +21.26% | 14 | Feb 26, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Market Outperform | $140 → $132 | $90.66 | +45.60% | 14 | Feb 26, 2026 | |
| SION Sionna Therapeutics | Initiates: Market Outperform | $63 | $37.32 | +68.81% | 1 | Feb 24, 2026 | |
| QNCX Quince Therapeutics | Downgrades: Market Perform | n/a | $0.11 | - | 3 | Jan 30, 2026 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Market Outperform | $527 → $745 | $444.83 | +67.48% | 15 | Jan 20, 2026 | |
| DBVT DBV Technologies | Maintains: Market Outperform | $21 → $45 | $20.58 | +118.66% | 16 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $33 → $35 | $5.21 | +571.79% | 9 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $11 → $10 | $5.25 | +90.48% | 10 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $29 → $28 | $16.94 | +65.29% | 6 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $15 → $14 | $3.50 | +300.00% | 14 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $27 → $25 | $8.22 | +204.14% | 10 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $20 | $8.72 | +129.36% | 1 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $20 → $29 | $8.76 | +231.05% | 18 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $4.60 | +291.73% | 13 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $52 | $25.42 | +104.56% | 12 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $1.82 | +339.56% | 8 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $0.66 | +2,171.69% | 3 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $5.94 | +219.87% | 9 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $38 | $28.00 | +35.71% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $50 | $40.88 | +22.31% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $90 | $43.63 | +106.28% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $126.30 | - | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Accumulate | $420 → $485 | $516.06 | -6.02% | 1 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $64 | $9.36 | +583.76% | 11 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $24 | $27.32 | -12.15% | 1 | May 12, 2023 |
Spruce Biosciences
Mar 10, 2026
Maintains: Market Outperform
Price Target: $180 → $170
Current: $60.06
Upside: +183.05%
Crinetics Pharmaceuticals
Mar 2, 2026
Maintains: Market Outperform
Price Target: $105 → $96
Current: $37.49
Upside: +156.07%
Rhythm Pharmaceuticals
Feb 27, 2026
Maintains: Market Outperform
Price Target: $167 → $176
Current: $87.38
Upside: +101.42%
Structure Therapeutics
Feb 27, 2026
Maintains: Market Outperform
Price Target: $120 → $113
Current: $53.75
Upside: +110.23%
Protagonist Therapeutics
Feb 26, 2026
Maintains: Market Outperform
Price Target: $102 → $112
Current: $92.36
Upside: +21.26%
Mirum Pharmaceuticals
Feb 26, 2026
Maintains: Market Outperform
Price Target: $140 → $132
Current: $90.66
Upside: +45.60%
Sionna Therapeutics
Feb 24, 2026
Initiates: Market Outperform
Price Target: $63
Current: $37.32
Upside: +68.81%
Quince Therapeutics
Jan 30, 2026
Downgrades: Market Perform
Price Target: n/a
Current: $0.11
Upside: -
Madrigal Pharmaceuticals
Jan 20, 2026
Maintains: Market Outperform
Price Target: $527 → $745
Current: $444.83
Upside: +67.48%
DBV Technologies
Dec 17, 2025
Maintains: Market Outperform
Price Target: $21 → $45
Current: $20.58
Upside: +118.66%
Nov 14, 2025
Maintains: Market Outperform
Price Target: $33 → $35
Current: $5.21
Upside: +571.79%
Nov 13, 2025
Maintains: Market Outperform
Price Target: $11 → $10
Current: $5.25
Upside: +90.48%
Nov 11, 2025
Maintains: Market Outperform
Price Target: $29 → $28
Current: $16.94
Upside: +65.29%
Nov 7, 2025
Maintains: Market Outperform
Price Target: $15 → $14
Current: $3.50
Upside: +300.00%
Nov 5, 2025
Maintains: Market Outperform
Price Target: $27 → $25
Current: $8.22
Upside: +204.14%
Nov 3, 2025
Initiates: Market Outperform
Price Target: $20
Current: $8.72
Upside: +129.36%
Oct 1, 2025
Maintains: Market Outperform
Price Target: $20 → $29
Current: $8.76
Upside: +231.05%
Aug 19, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $4.60
Upside: +291.73%
Aug 13, 2025
Maintains: Market Outperform
Price Target: $55 → $52
Current: $25.42
Upside: +104.56%
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $8
Current: $1.82
Upside: +339.56%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $0.66
Upside: +2,171.69%
May 23, 2025
Reiterates: Market Outperform
Price Target: $19
Current: $5.94
Upside: +219.87%
Apr 10, 2025
Initiates: Market Outperform
Price Target: $38
Current: $28.00
Upside: +35.71%
Dec 18, 2024
Maintains: Market Outperform
Price Target: $55 → $50
Current: $40.88
Upside: +22.31%
Dec 16, 2024
Reiterates: Market Outperform
Price Target: $90
Current: $43.63
Upside: +106.28%
Dec 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $126.30
Upside: -
Nov 13, 2024
Downgrades: Accumulate
Price Target: $420 → $485
Current: $516.06
Upside: -6.02%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $64
Current: $9.36
Upside: +583.76%
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $27.32
Upside: -12.15%